InMed Pharmaceuticals (INM) Stock Statistics & Valuation Metrics

InMed Pharmaceuticals has a market cap or net worth of $7.64M. The enterprise value is $4.54.

InMed Pharmaceuticals has 5,493,735 shares outstanding. The number of shares has decreased by -2.65% in one year.

InMed Pharmaceuticals’s return on equity (ROE) is -11.68 and return on invested capital (ROIC) is -920.47%.

The current PE Ratio of InMed Pharmaceuticals is ―. InMed Pharmaceuticals’s PEG ratio is 0.00793.

In the last 12 months, InMed Pharmaceuticals had revenue of 3.18B and earned -12.56M in profits. Earnings per share was -3.12.

In the last 12 months, operating cash flow was -10.14M and capital expenditures 9.00, giving a free cash flow of -10.14M billion.

InMed Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

InMed Pharmaceuticals upcoming earnings date is Nov 6, 2026, Before Open (Confirmed).

InMed Pharmaceuticals as a current ratio of 1.37, with Debt / Equity ratio of 0.00%

In the past 12 months, InMed Pharmaceuticals has paid 0.00 in taxes.

InMed Pharmaceuticals EV to EBITDA ratio is -0.46, with an EV/FCF ratio of >-0.01.

InMed Pharmaceuticals has $2.23M in cash and marketable securities with $0.00 in debt, giving a net cash position of $2.23M billion.

Gross margin is 14.92%, with operating margin of -0.31%, and net profit margin of -0.40%.

The average price target for InMed Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―